{"transactions":[{"id":682790,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":91,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":548,"derivative":{"underlying":"Common Stock","underlying_shares":91},"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682789,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":90,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":179,"derivative":{"underlying":"Common Stock","underlying_shares":90},"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682788,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":64,"price":4.55,"value":291.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8679,"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682787,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8743,"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":711021,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:02.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":18750,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001193125-26-300914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300914/ownership.xml","form_type":"4"}},{"id":771239,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":91,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":639,"derivative":{"underlying":"Common Stock","underlying_shares":91},"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771238,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":89,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":269,"derivative":{"underlying":"Common Stock","underlying_shares":89},"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771237,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":59,"price":7.53,"value":444.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares sold to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8562,"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771236,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":true,"shares":180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8621,"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":848195,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-11T22:39:08.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":56250,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001193125-26-102617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526102617/ownership.xml","form_type":"4"}}]}